{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:06Z","timestamp":1759017966790,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.annder.2019.08.020","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T07:57:02Z","timestamp":1579161422000},"page":"173-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilisation en pratique du rituximab en 2nde ligne et au-del\u00e0 dans le traitement du pemphigus: s\u00e9rie r\u00e9trospective"],"prefix":"10.1016","volume":"147","author":[{"given":"M.","family":"Barroil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lerisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Negroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-S.","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pallure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bessis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Dereure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.08.020_bib0110","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1582-4934.2007.00033.x","article-title":"Immunopathology and molecular diagnosis of autoimmune bullous diseases","volume":"11","author":"Mihai","year":"2007","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.annder.2019.08.020_bib0115","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.annder.2016.09.147","article-title":"Incidence et mortalit\u00e9 du pemphigus en France","volume":"143","author":"Jelti","year":"2016","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.08.020_bib0120","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjd.12474","article-title":"Methotrexate in the treatment of pemphigus vulgaris: experience in 23\u00a0patients","volume":"169","author":"Tran","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.08.020_bib0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-015-0353-6","article-title":"Pemphigus vulgaris: an evidence-based treatment update","volume":"75","author":"Zhao","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.annder.2019.08.020_bib0130","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of Rituximab for the treatment of severe Pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2019.08.020_bib0135","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31\u00a0patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"year":"2018","series-title":"Protocole National de diagnostic et de soins (PNDS) Pemphigus [Internet]","key":"10.1016\/j.annder.2019.08.020_bib0140"},{"key":"10.1016\/j.annder.2019.08.020_bib0145","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2019.08.020_bib0150","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","article-title":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47\u00a0patients","volume":"68","author":"Leshem","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.08.020_bib0155","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2019.08.020_bib0160","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center","volume":"78","author":"Vinay","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.08.020_bib0165","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42\u00a0cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.08.020_bib0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamadermatol.2017.5176","article-title":"Rituximab as single long-term maintenance therapy in patients with difficult-to-treat Pemphigus","volume":"154","author":"Sanchez","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2019.08.020_bib0175","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2019.08.020_bib0180","series-title":"Blistering diseases","first-page":"533","article-title":"The treatment of Pemphigus Vulgaris and Pemphigus Foliaceus","author":"Kim","year":"2015"},{"key":"10.1016\/j.annder.2019.08.020_bib0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaad.2018.01.029","article-title":"A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab","volume":"79","author":"Saleh","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.08.020_bib0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13555-012-0017-3","article-title":"Rituximab in the treatment of pemphigus vulgaris","volume":"2","author":"Zakka","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.annder.2019.08.020_bib0195","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ejim.2017.11.014","article-title":"Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: Report of 11\u00a0cases and review of the literature","volume":"50","author":"Alexandre","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.annder.2019.08.020_bib0200","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.08.020_bib0205","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.annder.2019.08.020_bib0105","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155\u00a0pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819310737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819310737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:08:28Z","timestamp":1758971308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819310737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0151963819310737"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.08.020","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilisation en pratique du rituximab en 2nde ligne et au-del\u00e0 dans le traitement du pemphigus: s\u00e9rie r\u00e9trospective","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}